Gene therapy experts

Gene therapy treats disease at the level of the genome rather than its symptoms, and the hard part is delivering the therapy to the tissue it was built for.

2 experts, updated 22 Oct 2026

The experts 2

Dr Patrick E. SewellFounder and Chief Science OfficerGene and cell therapy delivery, from the laboratory to the patient

Sauny SewellDirector of Clinical AffairsPatient care and long-term follow-up in gene therapy and healthspan medicine

What our gene therapy experts do

Gene therapy work at Triple Helix Science starts with the mechanism: identifying the genetic driver behind a disease, then building a therapeutic protocol against it rather than against the symptoms it produces. The protocol is held as proprietary, IP-protected intellectual property. From there the question is delivery, getting the construct into the tissue it was built for, whether that is tumour tissue in oncology or brain tissue in neurodegeneration. Triple Helix Science then takes the protocol into human trials, and reports a completed Phase 1 trial showing reversal of dementia progression.

How they work

Gene therapy experts at Triple Helix Science work from the position that ageing is systemic, so a correction in one organ system is assessed for what it does to the others. Interventions are designed across cellular energy, brain health and muscle function together rather than as separate programmes. Gene therapy is paired in house with stem cell biology, so repairing damaged tissue and correcting the genetic instruction behind the damage are one piece of work. The endpoint held to is healthspan, years lived in good physical and cognitive health, not lifespan alone.

When to bring them in

Gene therapy experts are the right people when an institution is looking at the cause of a disease rather than its management: a sovereign health system facing an ageing population, a research university with a genetic target and no delivery route, or a pharmaceutical organisation needing a protocol taken through human trials. Triple Helix Science works with governments, sovereign health systems, universities, sovereign wealth funds and enterprise pharmaceutical organisations, and does not operate direct to consumer. Engagements are built around national-scale delivery.

Newsletters

The most recent piece, published under their own names.

Dr Patrick E. Sewell in The Third StrandThe economics of preventive precision medicine22 Oct 2026

Media reaction

Democratising gene and cell therapy

"Gene and cell therapies are no longer a luxury for the elite. The economies of scale are here, and they're here now. These therapies have real use cases, from the most complex cancers to Alzheimer's and neurodegeneration, and they could transform healthcare systems worldwide. For the first time, preventative healthcare can be democratised on a global scale."

Dr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026

Patient experience in gene therapy

"Too often the patient is an afterthought in next-generation medicine. We talk about the science of gene therapy, but far less about what it's like to receive it. Nurse-led care that prepares patients and stays with them for years is one of the gaps we must close if gene therapy is going to reach more people."

Sauny Sewell, Director of Clinical Affairs, Triple Helix Science20 Oct 2026

Longevity, healthspan and preventative care

"'Longevity' is a marketing term. The therapies behind healthspan are not. They're scientifically robust, evidenced and tested, and if our field is going to flourish, that's the story we need to tell. Too many healthcare systems are built on reactive disease management, billing patients for expensive drugs year after year. Patients deserve better, and it's only a matter of time before a preventative model spreads globally."

Dr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026

1 of 3

Questions about gene therapy experts

The questions we get asked most about gene therapy, answered plainly.

What is gene therapy?

Gene therapy treats disease by altering the genetic material inside a patient's cells, so the underlying cause is addressed rather than the symptoms managed. Approaches include correcting a faulty gene, supplying a working copy, or changing how strongly a gene is expressed. Triple Helix Science develops gene therapy as proprietary, IP-protected therapeutic protocols, paired with stem cell biology in regenerative medicine and with immunotherapy in oncology.

What does working with a gene therapy expert involve?

A gene therapy engagement runs from developing the therapeutic protocol, through the problem of delivering it into the target tissue, to human trials. Triple Helix Science works at institutional level, partnering with governments, sovereign health systems, research universities, sovereign wealth funds and enterprise pharmaceutical organisations. Triple Helix Science is not a direct-to-consumer provider and does not treat individual patients.

How do you know if a gene therapy programme is working?

A gene therapy programme is judged on what changes in the patient and in the target tissue, measured against the expected course of the disease rather than against activity in culture. Triple Helix Science reports completing a Phase 1 human trial showing reversal of dementia progression. The broader measure Triple Helix Science works to is healthspan, meaning years lived in good physical and cognitive health.

Is gene therapy the same as stem cell therapy?

No. Gene therapy changes the genetic instructions inside cells a patient already has, while stem cell therapy supplies new cells able to become the tissue that has been lost or damaged. The two are frequently combined. Triple Helix Science's regenerative medicine work puts stem cell biology together with targeted gene therapies to repair damaged tissue.

When does an organisation need gene therapy expertise?

Gene therapy expertise is needed when a condition traces back to genetic and cellular mechanisms rather than to a symptom that can be managed, which covers oncology, neurodegeneration, metabolic disease and tissue repair. Triple Helix Science works with sovereign health systems, research universities and pharmaceutical organisations planning intervention at national scale. Individuals seeking treatment for themselves are not served by Triple Helix Science.

Contact an expert

Get in touch with an expert on gene therapy for comment, an interview or a question.

Straight to the Triple Helix Science press team.